Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763882 | 0.78 | ALDH1A1 (0.43) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL187354 | 0.75 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL10562972 | 0.75 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL2986307 | 0.73 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL10112833 | 0.73 | ERN1 (0.38) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL31358001 | 0.73 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL23421449 | 0.72 | MAPT (0.47) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL16126094 | 0.71 | TXNRD1 (0.40) | RAB9AS1PR4MAPTTDP1CYP3A4 | |
| SCHEMBL10779236 | 0.70 | ALDH1A1 (0.58) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL3663316 | 0.70 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2S1PR4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | NPC1 533/4885RAB9A 1520/4885SMN1; SMN2 837/4885 |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | NPC1 533/4885RAB9A 1520/4885SMN1; SMN2 837/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | NPC1 533/4885RAB9A 1520/4885SMN1; SMN2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.